Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATLANTIS maintenance targeted therapy trial in metastatic urothelial cancer
ISRCTN25859465Phase 2Completed
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- Nov 2016
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of rucaparib, enzalutamide and cabozantinib in transitional cell carcinoma (TCC) (6 arms), sponsored by NHS Greater Glasgow and Clyde. Primary endpoint: Progression-free survival. Started Nov 2016; status: completed.
02
Drugs
rucaparibenzalutamidecabozantinib
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on ISRCTN25859465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN25859465.